NURS5205 Chap.5 Dyslipidaemia, Coronary Disease and ACS
Dyslipidaemia, Coronary Disease and ACS
This chapter uses a timeline to separate long-term lipid and coronary prevention, time-critical acute coronary syndrome care and secondary prevention after an event. It connects pharmacotherapy to pathophysiology, treatment purpose, precautions, adverse effects and monitoring. The answer order follows the patient: urgent recognition and escalation first, acute protocol-led care next, then long-term recurrence reduction.
What this chapter covers
- 01
Dyslipidaemia and cardiovascular risk
- 02
Coronary disease pathophysiology
- 03
Acute coronary syndrome recognition
- 04
Immediate treatment goals
- 05
Bleeding and haemodynamic monitoring
- 06
Post-event secondary prevention
Worked example · free
Reprioritising new chest discomfort
- +1The study marks shown are not a University mark allocation. Stop the routine review, assess the patient and obtain urgent help under the acute chest-pain pathway.
- +1Communicate symptom onset, observations, history and current medicines without delaying escalation.
- +1Anticipate protocol-directed tests and medicines while checking relevant allergies, contraindications and bleeding risk.
- +1After stabilisation, reconnect lipid and secondary-prevention therapy to recurrence reduction and monitoring.
Key terms
- Dyslipidaemia
- An abnormal lipid profile considered within overall cardiovascular risk and established disease status.
- Acute coronary syndrome
- A group of acute conditions caused by reduced coronary blood flow that require urgent assessment and treatment.
- Secondary prevention
- Therapy and behaviour change intended to reduce recurrence after established cardiovascular disease or an event.
- Antiplatelet therapy
- Treatment that reduces platelet activation and thrombosis while increasing bleeding risk that requires surveillance.
Dyslipidaemia, Coronary Disease and ACS FAQ
Why should dyslipidaemia not be treated as an isolated number?
Lipid results sit inside total cardiovascular risk and established disease status. Medicine benefit, intensity and monitoring depend on the patient's broader risk, comorbidity, adverse-effect profile and ability to continue therapy.
What is the first move in a suspected ACS case?
Recognise the presentation, assess immediate stability and activate the local urgent pathway. A list of coronary medicines without escalation, contraindication checks or monitoring misses the time-critical problem and the nurse's role in safe care.
How is secondary prevention different from acute treatment?
Acute treatment addresses the current event and immediate complications. Secondary prevention reduces future events through continuing pharmacotherapy, risk-factor management, education and follow-up. Some medicines cross both phases, but their purpose and monitoring should still be stated.
Why should an ACS answer be chronological?
The patient's immediate risk determines the first action. Recognition, assessment and escalation come before a detailed chronic prevention plan. Chronology makes it clear which therapy addresses the event and which reduces later recurrence.
What should be checked before protocol-directed medicines?
Relevant allergies, contraindications, haemodynamic state, bleeding risk and recent medicine exposure should be communicated as the urgent pathway proceeds. The exact checks depend on the authorised intervention and patient context.
How can transition of care create medicine risk?
Acute additions, changed doses and intended durations can become unclear at discharge. Reconciliation and purpose-based education help prevent duplication, premature cessation and confusion about which medicines continue for secondary prevention.
What belongs in coronary monitoring?
Choose observations that match the phase and medicine role, such as symptoms, haemodynamics, bleeding, relevant pathology, adverse effects and adherence. A generic monitoring list is weaker than a patient-specific reason for each observation.
How should possible ACS be communicated before diagnosis?
Report the symptom character, onset, associated features, observations, history and recent medicines. Urgent action can be justified by concerning evidence without claiming a final diagnosis that has not yet been established.
Why can bleeding risk change acute care?
Several protocol-directed antithrombotic strategies reduce clot-related harm while increasing bleeding risk. Recent medicines, active bleeding, allergy and other contraindication evidence should be available during authorised decision-making.
What makes discharge education purpose based?
Explain why each medicine continues, how it should be used, important warning signs and any planned duration. Purpose helps the patient distinguish apparently similar tablets and reduces accidental cessation or duplication.
Why is a lipid result only one part of prevention?
Overall cardiovascular risk, established disease, tolerance, interactions and adherence all affect management. Connect the laboratory result to the patient's broader prevention pathway rather than treating it alone.
Exam move
Draw the coronary timeline and place each medicine role at prevention, acute care or secondary prevention. For every class, add one harm and one observation that matters. Rehearse original cases that begin as routine reviews and become urgent, because they test whether you can reorder priorities.
When revising lipid therapy, always connect the result to overall risk rather than presenting treatment as a response to one number alone. Build a discharge reconciliation exercise that labels each medicine by purpose and duration. Practise a concise urgent handover using symptom onset, associated features, observations, relevant history and recent medicines.
Finish by distinguishing what is known from what still requires diagnostic confirmation.
Working through Dyslipidaemia, Coronary Disease and ACS in NURS5205? Sia is AskSia’s AI Nursing tutor — ask any NURS5205 Dyslipidaemia, Coronary Disease and ACS question and get a clear, step-by-step explanation grounded in how NURS5205 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.
